Claims for Patent: 7,056,655

Summary for Patent: 7,056,655

Title:	Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
Abstract:	The present invention relates to novel methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism. One determines and monitors the level of parathyroid hormone agonist and parathyroid hormone antagonist in the renal patient. The parathyroid hormone suppressing therapeutic is administered to the patient so as to minimize the level of parathyroid hormone antagonist.
Inventor(s):	Cantor; Thomas L. (El Cajon, CA)
Assignee:	Scantibodies Laboratory, Inc. (Santee, CA)
Application Number:	10/286,465
Patent Claims:	1. A method for monitoring and guiding therapeutic suppression of parathyroid hormone in a renal patient having secondary hyperparathyroidism, said method comprising: a) obtaining a sample of blood, serum or plasma from said renal patient; b) determining and monitoring the level of a parathyroid hormone (PTH) agonist in said sample, wherein said agonist comprises a contiguous segment of human PTH having the amino acid sequence SEQ ID NO:1, wherein said segment starts at position 1 of human PTH, and ends at any position from position 34 through position 84 of human PTH; c) determining and monitoring the level of a PTH antagonist in said sample, wherein said antagonist comprises a contiguous portion of human PTH having the amino acid sequence SEQ ID NO:1, wherein said portion starts at any position from position 2 through position 33 of human PTH, ends at any position from position 35 through position 84 of human PTH, and has a minimal length of three amino acid residues; and d) administering a therapeutic that suppresses PTH agonist to the patient whereby the amount of therapeutic administered is adjusted such that PTH agonist levels are decreased and the level of PTH antagonist is minimized. 2. The method of claim 1, wherein the therapeutic is administered in increasing increments from a nominal amount. 3. The method of claim 1, wherein the patient is already receiving the therapeutic, also comprising adjusting the amount of therapeutic until the level of PTH antagonist is minimized. 4. The method of claim 1, wherein the therapeutic is selected from the group consisting of vitamin D or vitamin D analogue treatment, calcium treatment, or calcimimetic administration. 5. The method of claim 4, wherein the vitamin D analogue comprises paricalcitrol, calcitriol, maxacalcitol, alfacalcidol, calcifediol, or ergocalciferol. 6. The method of claim 1, wherein the PTH agonist level is further compared with the PTH antagonist level. 7. The method of claim 1, wherein the PTH antagonist level is determined by determining the patient's total parathyroid hormone level and subtracting the PTH agonist level from the total parathyroid hormone level. 8. The method of claim 1, wherein the patient's total parathyroid hormone level is determined, and the PTH agonist level is further compared with the total parathyroid hormone level. 9. The method of claim 1, wherein the patient's total parathyroid hormone level is determined, and the PTH antagonist level is further compared with the total parathyroid hormone level. 10. The method of claim 1, wherein the PTH agonist level is further compared with the PTH antagonist level in the form of a ratio or proportion. 11. The method of claim 1, wherein the hyperparathyroidism is caused by chronic renal failure. 12. The method of claim 1, wherein the PTH agonist level and the PTH antagonist level are determined using an immunoassay. 13. The method of claim 12, wherein the PTH agonist level is determined using an antibody that distinguishes PTH agonist from PTH antagonist. 14. The method of claim 12, wherein the PTH antagonist level is determined using an antibody that distinguishes PTH agonist from PTH antagonist. 15. The method of claim 1, further comprising monitoring for vascular calcification in the patients. 16. The method of claim 15, wherein the vascular calcification is monitored by monitoring alkaline phosphatase level. 17. The method of claim 1, wherein the patient is already receiving the therapeutic, also comprising terminating the therapeutic administration for a time sufficient to allow the patient to return to at least a relatively non-suppressed state. 18. The method of claim 17, wherein the time sufficient to allow the patient to return to at least a relatively non-suppressed state is between about three months to about six months. 19. The method of claim 17, wherein the time sufficient to allow the patient to return to at least a relatively non-suppressed state is about three minutes to about twenty minutes. 20. The method of claim 1, wherein the PTH agonist is a peptide having an amino acid sequence of human PTH.sub.1-84 set forth in SEQ ID NO:1. 21. The method of claim 1, wherein the PTH antagonist is a peptide having an amino acid sequence of human PTH7 84 (SEQ ID NO: 7). 22. The method of claim 1, wherein the PTH agonist level and the PTH antagonist level determinations are further compared with bone biopsy data. 23. The method of claim 22, wherein, after administration of the therapeutic, the PTH agonist level and the PTH antagonist level determinations are compared with bone biopsy data. 24. The method of claim 10, wherein the ratio or proportion determination is further compared with bone biopsy data. 25. A method for monitoring and guiding therapeutic suppression of parathyroid hormone having the sequence set forth in SEQ ID NO:1 in a renal patient having secondary hyperparathyroidism, said method comprising: a) obtaining a sample of blood, serum or plasma from the patient; b) determining and monitoring the level of a parathyroid hormone (PTH) antagonist in the sample, wherein said antagonist comprises a contiguous portion of human PTH having the amino acid sequence SEQ ID NO:1, wherein said portion starts at any position from position 2 through position 33 of human PTH, ends at any position from position 35 through position 84 of human PTH, and has a minimal length of three amino acid residues; and c) administering to the patient a therapeutic capable of suppressing a PTH agonist, whereby the amount of therapeutic administered is adjusted such that the level of PTH antagonist is minimized in the patient. 26. The method of claim 25, wherein the therapeutic is administered in increasing increments from a nominal amount. 27. The method of claim 25, wherein the therapeutic is selected from the group consisting of vitamin D, a vitamin D analogue, calcium, or a calcimimetic. 28. The method of claim 27, wherein the vitamin D analogue comprises paricalcitrol, calcitriol, maxacalcitol, alfacalcidol, calcifediol, or ergocalciferol. 29. The method of claim 25, further comprising monitoring for vascular calcification in said patients. 30. The method of claim 29, wherein vascular calcification is monitored by monitoring alkaline phosphatase levels. 31. The method of claim 25, wherein the patient is already receiving the therapeutic, also comprising terminating the therapeutic administration for a time sufficient to allow the patient to return to at least a relatively non-suppressed state. 32. The method of claim 31, wherein the time sufficient to allow the patient to return to at least a relatively non-suppressed state is between about three months to about six months. 33. The method of claim 31, wherein the time sufficient to allow the patient to return to at least a relatively non-suppressed state is about three minutes to about twenty minutes. 34. The method of claim 25, wherein the PTH antagonist level is determined by determining the total PTH level and the PTH agonist level, and subtracting the PTH agonist level from the total PTH level, wherein the PTH antagonist level is then compared with the PTH agonist level. 35. A method for determining an appropriate dosage of a therapeutic for suppression of parathyroid hormone having the sequence set forth in SEQ ID NO:1 in a renal patient having secondary hyperparathyroidism, said method comprising: a) administering a therapeutic capable of suppressing PTH to said renal patient; b) obtaining a sample of blood, plasma or serum from said renal patient; c) determining the level of a PTH antagonist in the sample, wherein said antagonist comprises a contiguous portion of human PTH having the amino acid sequence SEQ ID NO:1, wherein said portion starts at any position from position 2 through position 33 of human PTH, ends at any position from position 35 through position 84 of human PTH, and has a minimal length of three amino acid residues; and d) adjusting the dosage of said therapeutic up or down; e) monitoring the level of said PTH antagonist in said patient by obtaining an additional sample of blood, plasma, or serum from the patient and measuring the level of said PTH antagonist in said sample; and f) further adjusting the dosage of said therapeutic up or down until the level of said PTH antagonist is minimized. 36. The method of claim 35, wherein said PTH antagonist comprises PTH.sub.7-84 as set forth in SEQ ID NO: 7. 37. The method of claim 35, further comprising monitoring the level of a PTH agonist in said patient, wherein said agonist comprises a contiguous segment of human PTH having the amino acid sequence SEQ ID NO:1, wherein said segment starts at position 1 of human PTH, and ends at any position from position 34 through position 84 of human PTH. 38. The method of claim 36, wherein said PTH agonist comprises PTH1 84 as set forth in SEQ ID NO:1. 39. The method of claim 38, whereby the amount of therapeutic administered is adjusted to lower the measured levels of PTH antagonist and PTH agonist in the patient.

Details for Patent 7,056,655

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26